Pyrosequencing in Epigenetics — Pre-designed Assays for Reliable Detection and Accurate Quantification of DNA Methylation Across the Human Genome

In epigenetic DNA methylation studies, next-generation sequencing delivers massive amounts of data on genome-wide methylation patterns, from which specific targets need to be validated as physiologically relevant epigenetic modifications. This validation process is challenging because even subtle changes in location and frequency of methylated sites appear to be significant. Pyrosequencing is an ideal validation platform because it rapidly quantifies single and multiple methylation sites in a single assay. As a result, this technology is becoming a standard for data analysis in epigentic research.

Assay design for methylation analysis is often complicated because primer binding is impacted by the conversion of cytosine into thymidine at non-CpG sites. To address this issue, QIAGEN has recently developed the pre-designed, gene-specific PyroMark CpG Assays covering the entire human genome. These assays facilitate analysis of CpG methylation and grant flexibility in choice of target region and coverage of the CpG island to be analyzed.

In this webinar, you learn about:
  • Quantification in CpG methylation analysis using QIAGEN's Pyrosequencing technology
  • Important considerations for a successful assay design
  • The success rate of pre-designed Pyrosequencing assays
  • The comprehensive coverage of the human genome by PyroMark CpG assays
  • Features that facilitate finding the right assay and integrating it into the Pyrosequencing workflow

Dr. Gerald Schock, Associate Director PyroMark, QIAGEN GmbH

Gerald Schock

Dr. Gerald Schock is Associate Director for QIAGEN’s Pyrosequencing product line. Dr. Schock studied Biology and Biochemistry at the University of Mainz, Germany and at the University College of Wales, Aberystwyth, UK. He joined QIAGEN after receiving his Ph.D. in 1996, and has held positions in Sales, Regional Marketing, and Global Marketing, where he built up the epigenetics portfolio before assuming responsibility for the Life Science Pyrosequencing portfolio.